000			03308nam a22004577a 4500
700			_aSequeira, Sean _bMUMH _cOrthopaedic Surgery Residency _dMD _eResident PGY 2
008			230721s20232023 xxu||||| |||| 00| 0 eng d
022			_a2197-1153
024			_a10.1186/s40634-023-00620-0 [doi]
024			_a10.1186/s40634-023-00620-0 [pii]
024			_aPMC10234955 [pmc]
040			_aOvid MEDLINE(R)
099			_a37261550
245			_aHormone replacement therapy does not increase thrombosis risk following THA: a national database study.
251			_aJournal of Experimental Orthopaedics. 10(1):60, 2023 Jun 01.
252			_aJ. exp. orthop.. 10(1):60, 2023 Jun 01.
253			_aJournal of experimental orthopaedics
260			_c2023
260			_fFY2023
260			_p2023 Jun 01
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2023-07-21
520			_aCONCLUSIONS: HRT was not found to be an independent risk factor for thromboembolism following THA. Further research is warranted to better delineate the ideal perioperative medical management of HRT users undergoing THA. Copyright © 2023. The Author(s).
520			_aMETHODS: Women aged > 40 years of age who underwent primary THA were identified from a retrospective database review. A control group of non-HRT users was matched using propensity scoring to HRT users. Rates of 90-day medical complications and 1-year surgery-related complications were compared between cohorts using odds ratios. Postoperative anticoagulation regimens were also compared.
520			_aPURPOSE: Hormone replacement therapy (HRT) causes a significant increase in the risk of venous thrombosis. The risk of medical and surgery-related complications among women taking HRT following total hip arthroplasty (THA) is poorly understood, and there are currently no guidelines in place regarding venous thromboembolism prophylaxis in this patient population. The purpose of this study was to evaluate the frequency of early medical and surgery-related complications following THA among women taking HRT.
520			_aRESULTS: There were 3,936 patients in the HRT cohort who were matched to 39,360 patients not taking HRT. There were no significant differences in rates of DVT (OR 0.94, p = 0.6601) or PE (OR 0.80, p = 0.4102) between cohorts. Patients on HRT were more likely to sustain a dislocation (OR 1.35, p = 0.0269) or undergo revision surgery (OR 1.23, p = 0.0105). HRT patients were more likely to be prescribed warfarin (OR 1.21, p = 0.0001) or enoxaparin (OR 1.18, p = 0.0022) and less likely to be prescribed rivaroxaban (OR 0.62, p < 0.0001) compared to controls.
546			_aEnglish
650			_zAutomated
651			_aMedStar Union Memorial Hospital
656			_aOrthopaedic Surgery
656			_aOrthopaedic Surgery Residency
657			_aJournal Article
700			_aBoucher, Henry R _bMUMH
700			_aHasenauer, Mark D _bMUMH
700			_aMcCormick, Brian P _bMUMH
790			_aBoucher HR, Hasenauer MD, McCormick BP, Sequeira SB
856			_uhttps://dx.doi.org/10.1186/s40634-023-00620-0 _zhttps://dx.doi.org/10.1186/s40634-023-00620-0
858			_zhttp://orcid.org/0000-0002-4883-9927 _yMcCormick, Brian P _uhttp://orcid.org/0000-0002-4883-9927
942			_cART _dArticle
999			_c13026 _d13026